Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Hanga C Galfalvy

3 papers in the library · 26 citations · publishing 2023-2026

Papers

Mindfulness-based real-time fMRI neurofeedback: a randomized controlled trial to optimize dosing for depressed adolescents.

BMC Psychiatry October 17, 2023 Paul A Bloom, David Pagliaccio, Jiahe Zhang et al. 17 citations

Adolescents with major depressive disorder (MDD) may benefit from a non-invasive technique that combines mindfulness with real-time fMRI neurofeedback (mbNF) to reduce activity in the default mode network (DMN), a brain network linked to rumination. In a planned trial, 90 adolescents aged 13–18 with MDD will be randomly assigned to receive either 15 or 30 minutes of mbNF. During the procedure, participants practice mindfulness while a ball on a screen moves based on their brain activity, targeting the frontoparietal network relative to the DMN. The study will test whether mbNF reduces functional connectivity within the DMN and whether longer dosing produces greater effects, with secondary outcomes including changes in depressive symptoms and rumination.

Acute Dissociation and Ketamine's Antidepressant and Anti-Suicidal Ideation Effects in a Midazolam-Controlled Trial.

The International Journal of Neuropsychopharmacology April 1, 2024 Sumra Sajid, Hanga C Galfalvy, John G Keilp et al. 9 citations

In a randomized, midazolam-controlled trial of 40 suicidal, depressed participants given intravenous ketamine, acute dissociative and psychotomimetic effects were not associated with changes in suicidal ideation or depressive symptoms from before to after infusion. Norketamine showed a trend-level, moderate inverse correlation with dissociative symptoms on Day 1 post-injection, suggesting dissociation may be more an effect of the parent drug. Dehydronorketamine correlated with dissociative symptoms at multiple time points. No evidence was found that ketamine's acute, transient dissociative or psychotomimetic effects contribute to its antidepressant or anti-suicidal actions.

Increased morning cortisol after ketamine treatment for suicidal depression: Exploratory report from a randomized trial.

Journal of Affective Disorders November 1, 2026 Tse-Hwei Choo, Hanga C Galfalvy, John G Keilp et al.

A midazolam-controlled trial of intravenous ketamine for suicidal depressed patients found that ketamine rapidly reduced suicidal ideation within 24 hours. An exploratory analysis measured saliva cortisol awakening response at baseline and 24 hours after infusion. Waking cortisol significantly increased 24 hours after ketamine treatment. The increase in waking cortisol from baseline to post-infusion showed a small to medium, nonsignificant correlation with decreased suicidal ideation. These preliminary results, pending replication, align with evidence that moderate cortisol increases may enhance stress-resilience.